Recursion Pharmaceuticals Inc (NASDAQ:RXRX) traded at $10.53 at close of the session on Friday, February 14 and made an upward move of 23.88% on its previous day’s price.
Looking at the stock we see that its previous close was $8.50 and the beta (5Y monthly) reads 0.859 with the day’s price range being $9.04 – $10.755. In terms of its 52-week price range, RXRX has a high of $15.74 and a low of $5.60. The company’s stock has gained about 64.02% over that past 30 days.
Recursion Pharmaceuticals Inc has a market cap of $4.11 billion and is expected to release its quarterly earnings report in March.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at 19.04M, with a low of 8M and a high of 40.1M. The median projection represents growth squeezing down to 74.85% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for current year is expected to hit 67.8M, or 52.11% up from figures reported last year.
On the other hand, looking at the outlook for the RXRX stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of 50% Buy.
Based on estimates by 3 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 1 have rated the Recursion Pharmaceuticals Inc (RXRX) stock as a Hold, while 2 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is 38.10% off its SMA20 and 44.36% from its 50-day simple moving average. The RSI (14) is pointing at 75.25 while the volatility over the past week is 11.21% and jumps to 9.64% over the past one month. The beta value is 0.86, while the average true range (ATR) is currently pointing at 0.81. The average price target for the stock over the next 12 months is $11, with the estimates having a low of $6 and a high of $12. These price ends are 43.02% and -13.96% off the current price level respectively, although investors could be excited at the prospect of a -4.46% if the RXRX share price touches on the median price of $11.
Coming back to Recursion Pharmaceuticals Inc (NASDAQ:RXRX), we note that the average 3-month trading volume was 17.77 million, while that of the preceding 10-day period stands at 33.6 million. Current shares outstanding are 390.76 million.
The insiders hold 17.35% of the company’s shares while institutions hold 61.88%. The data shows that short shares as of 2025-01-31, stood at 63.75 million at a short ratio of 3.77. This represents a 1779.00 short interest in shares outstanding on 2025-01-31. Shares short fall in January from the previous month at 73.74 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock 55.77% up in year-to-date price movement.
